Skip to content

Ketamine research published in 2020

Page 5 of 8: studies 81 to 100 of 157, newest first. Back to the ketamine overview

Studies

Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence

Expert Opinion on Drug Safety June 15, 2020 Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al. 50 citations

ABSTRACT Objectives Rigorous clinical trials suggest ketamine is safe and well-tolerated in patients with treatment-resistant depression (TRD). There is a paucity of data on the safety and tolerability of ketamine in community-based clinics treating patients with TRD. Methods Retrospective data was analyzed from 203 patients with TRD who received repeat-dose IV ketamine. Safety was...

Subanesthetic ketamine exerts antidepressant-like effects in adult rats exposed to juvenile stress.

Brain Research June 13, 2020 Katsuhiro Aikawa, Takayuki Yoshida, Yu Ohmura et al.

Juvenile stress, like that caused by childhood maltreatment, is a significant risk factor for psychiatric disorders such as depression later in life. Recently, the antidepressant effect of ketamine, a noncompetitive N-methyl-d-aspartate receptor antagonist, has been widely investigated. However, little is known regarding its efficacy against depressive-like alterations caused by juvenile...

Characteristic patterns of EEG oscillations in sheep (Ovis aries) induced by ketamine may explain the psychotropic effects seen in humans.

Scientific Reports June 11, 2020 A U Nicol, A J Morton

Ketamine is a valuable anaesthetic and analgesic that in recent years has gained notoriety as a recreational drug. Recently, ketamine has also been proposed as a novel treatment for depression and post-traumatic stress disorder. Beyond its anaesthetic actions, however, the effects of ketamine on brain activity have rarely been probed. Here we examined the cortical electroencephalography (EEG)...

Affective Switch Associated With Oral, Low Dose Ketamine Treatment in a Patient With Treatment Resistant Bipolar I Depression. Case Report and Literature Review

Frontiers in Psychiatry June 3, 2020 Alina Wilkowska, Łukasz P. Szałach, Jakub Słupski et al. 9 citations

There is a growing evidence for the rapid and robust antidepressive effect of ketamine in unipolar and bipolar treatment resistant depression although evidence for the risk of affective switch is still limited. This case presents bipolar I disorder patient with treatment resistant depressive episode experiencing a switch to manic episode with mixed features shortly after receiving eight...

A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol

BMC Psychiatry June 2, 2020 J. Phillips, N. Jaworska, Elizabeth Kamler et al. 22 citations

Background Recent evidence underscores the utility of rapid-acting antidepressant interventions, such as ketamine, in alleviating symptoms of major depressive episodes (MDE). However, to date, there have been limited head-to-head comparisons of intravenous (IV) ketamine infusions with other antidepressant treatment strategies in large randomized trials. This study protocol describes an ongoing...

Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: Possible role of pro-synaptogenic signaling pathway.

Journal of Affective Disorders June 1, 2020 A. Camargo, A. P. Dalmagro, A. Zeni et al.

Background Augmentation therapies may be effective strategies to potentiate the ketamine's actions with lower potential for knock-on effects. Thus, this study investigated the ability of combined administration of guanosine plus ketamine to elicit an antidepressant-like effect associated with mTOR pathway modulation. The ability of this combined administration to exert an antidepressant-like...

Efficacy of Esketamine Augmentation in Major Depressive Disorder

The Journal of Clinical Psychiatry May 26, 2020 George I. Papakostas, Naji C. Salloum, Rebecca S. Hock et al. 107 citations

OBJECTIVE: Esketamine, the S-enantiomer of ketamine, was recently approved as a rapid-acting intranasal therapy for depression and is currently under development for suicidality. The authors sought to determine the efficacy of adjunctive intranasal esketamine in major depressive disorder (MDD). DATA SOURCES: A systematic search of PubMed/MEDLINE was conducted up to January 2019, in addition to...

Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents.

Journal of the Neurological Sciences May 15, 2020 Molly C Kalmoe, Alvin Janski, Charles F Zorumski et al.

N-methyl-d-aspartate receptor (NMDAR) antagonists, including ketamine and nitrous oxide, are currently intensely studied as rapid-acting antidepressant agents. Interestingly, both of these compounds are also drugs of abuse. Intravenous ketamine, a dissociative anesthetic that induces complex downstream effects via NMDARs, rapidly reduces depressive and suicidal symptoms in treatment-resistant...

The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder

Bipolar Disorders May 14, 2020 Roger S McIntyre, Orly Lipsitz, Nelson B Rodrigues et al. 64 citations

Abstract Objective To determine the effectiveness of intravenous (IV) ketamine on anxiety, irritability, agitation, and suicidality, in adults with treatment‐resistant major depressive disorder (MDD) or bipolar disorder (BD). Method Adults (N = 201) with treatment‐resistant MDD or BD received repeat‐dose IV ketamine treatment at a community‐based clinic. Mixed features were measured using...

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent

The Journal of Clinical Psychiatry May 11, 2020 Dong-Jing Fu, Dawn F. Ionescu, Xiang Li et al. 367 citations

OBJECTIVE: To compare esketamine to placebo, each in addition to standard-of-care treatment, for rapidly reducing major depressive disorder symptoms, including suicidal ideation. METHODS: This phase 3, double-blind, multicenter study (ASPIRE I), conducted between June 2017 and December 2018, enrolled 226 adults having major depressive disorder based on Diagnostic and Statistical Manual of...

Ketamine's Dose Related Multiple Mechanisms of Actions: Dissociative Anesthetic to Rapid Antidepressant.

Behavioural Brain Research May 8, 2020 E. Lavender, Mika Hirasawa-Fujita, E. Domino

Ketamine induces safe and effective anesthesia and displays unusual cataleptic properties that gave rise to the term dissociative anesthesia. Since 1970, clinicians only utilized the drug as an anesthetic or analgesic for decades, but ketamine was found to have rapid acting antidepressant effects in 1990s. Accumulated evidence exhibits NMDAR antagonism may not be the only mechanism of ketamine....

The neurophysiology of ketamine: an integrative review

Reviews in the Neurosciences May 5, 2020 Rebecca McMillan, Suresh Muthukumaraswamy 53 citations

The drug ketamine has been extensively studied due to its use in anaesthesia, as a model of psychosis and, most recently, its antidepressant properties. Understanding the physiology of ketamine is complex due to its rich pharmacology with multiple potential sites at clinically relevant doses. In this review of the neurophysiology of ketamine, we focus on the acute effects of ketamine in the...

DOI: 10.1515/revneuro-2019-0090 (opens in new tab) Ketamine Neurophysiology Neuroimaging Neurology +1

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials

The International Journal of Neuropsychopharmacology May 5, 2020 Ziad S. Saad, D. Hibar, Maggie Fedgchin et al. 43 citations

Abstract Background At ketamine and esketamine doses at which antidepressant doses are achieved, these agents are relatively selective, noncompetitive, N-methyl-D-aspartate receptor antagonists. However, at substantially higher doses, ketamine has shown mu-opioid receptor (MOR–gene symbol: OPRM1) agonist effects. Preliminary clinical studies showed conflicting results on whether naltrexone, a...

Generative modelling of the thalamo-cortical circuit mechanisms underlying the neurophysiological effects of ketamine

bioRxiv Preprint Server May 5, 2020 Alexander D Shaw, Suresh Muthukumaraswamy, Neeraj K. Saxena et al. 2 citations preprint

Cortical recordings of task-induced oscillations following subanaesthetic ketamine administration demonstrate alterations in amplitude, including increases at high-frequencies (gamma) and reductions at low frequencies (theta, alpha). To investigate the population-level interactions underlying these changes, we implemented a thalamo-cortical model (TCM) capable of recapitulating broadband...

DOI: 10.1101/688044 (opens in new tab) Full text (opens in new tab) Ketamine effects Ketamine mechanisms Computational neuroscience Brain modeling +7

A single psychotomimetic dose of ketamine decreases thalamocortical spindles and delta oscillations in the sedated rat

arXiv Preprint Archive May 4, 2020 Didier Pinault preprint

Background: In patients with psychotic disorders, sleep spindles are reduced, supporting the hypothesis that the thalamus and glutamate receptors play a crucial etio-pathophysiological role, whose underlying mechanisms remain unknown. We hypothesized that a reduced function of NMDA receptors is involved in the spindle deficit observed in schizophrenia. Methods: An electrophysiological multisite...

Full text (opens in new tab) Q-bio.nc Psychopharmacology Brain-waves Mental-health +1

Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Neural Regeneration Research May 1, 2020 Giulia Costa, Maria Antonietta De Luca, Gessica Piras et al.

Preclinical and clinical studies indicate that synthetic psychoactive substances, in addition to having abuse potential, may elicit toxic effects of varying severity at the peripheral and central levels. Nowadays, toxicity induced by synthetic psychoactive substances poses a serious harm for health, since recreational use of these substances is on the rise among young and adult people. The...

Modulation of amygdala reactivity following rapidly acting interventions for major depression.

Human Brain Mapping May 1, 2020 Joana R Loureiro, Amber M Leaver, Megha M Vasavada et al. 65 citations

Electroconvulsive therapy (ECT) and ketamine treatment both induce rapidly acting antidepressant effects in patients with major depressive disorder unresponsive to standard treatments, yet their specific impact on emotion processing is unknown. Here, we examined the neural underpinnings of emotion processing within and across patients (N = 44) receiving either ECT (N = 17, mean age: 36.8, 11.0...

Use of Various Doses of S-Ketamine in Treatment of Depression and Pain in Cervical Carcinoma Patients with Mild/Moderate Depression After Laparoscopic Total Hysterectomy

Medical Science Monitor April 27, 2020 Jie Wang, Yajun Wang, Xudong Xu et al. 80 citations

Background This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression. Material/Methods This randomized, double-blind, controlled study included 417 cervical carcinoma patients who received laparoscopic modified radical hysterectomy from April 2015 to July 2018 and who also had mild/moderate...